In Brief: Immunomedics CEA-Scan
Executive Summary
Immunomedics CEA-Scan: Diagnostic imaging agent demonstrates 60% accuracy in predicting tumor resectability in patients with known or suspected recurrent colorectal cancer compared to 47% for diagnosis via computed tomography, Immunomedics announces. In a 208-patient Phase III study, radioimmunodetection using the Tc-labeled Fab' fragment of the murine anti-CEA IMMU-4 monoclonal antibody was correct more often (69%) than CT (31%) when there were differing assessments of resectability, Immunomedics says. A PLA filing for CEA-Scan in 1991 resulted in a May 1994 "not approvable" letter from FDA. Immunomedics submitted the additional data in March in response to FDA's request to demonstrate the agent's clinical utility...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth